Lyell Immunopharma Stock Fundamentals
| LYEL Stock | USD 0.95 0.03 3.26% |
Lyell Immunopharma fundamentals help investors to digest information that contributes to Lyell Immunopharma's financial success or failures. It also enables traders to predict the movement of Lyell Stock. The fundamental analysis module provides a way to measure Lyell Immunopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lyell Immunopharma stock.
At this time, Lyell Immunopharma's Net Interest Income is quite stable compared to the past year. Interest Income is expected to rise to about 24.6 M this year, although the value of Total Revenue will most likely fall to about 123.5 K. Lyell | Select Account or Indicator |
Lyell Immunopharma Company Return On Asset Analysis
Lyell Immunopharma's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Lyell Immunopharma Return On Asset | -0.19 |
Most of Lyell Immunopharma's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lyell Immunopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Lyell Total Assets
Total Assets |
|
Based on the latest financial disclosure, Lyell Immunopharma has a Return On Asset of -0.1912. This is 97.81% lower than that of the Biotechnology sector and 99.19% lower than that of the Health Care industry. The return on asset for all United States stocks is 36.57% higher than that of the company.
Lyell Immunopharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lyell Immunopharma's current stock value. Our valuation model uses many indicators to compare Lyell Immunopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lyell Immunopharma competition to find correlations between indicators driving Lyell Immunopharma's intrinsic value. More Info.Lyell Immunopharma is rated fifth overall in return on equity category among its peers. It is rated fourth overall in return on asset category among its peers . At this time, Lyell Immunopharma's Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Lyell Immunopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Lyell Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lyell Immunopharma's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lyell Immunopharma could also be used in its relative valuation, which is a method of valuing Lyell Immunopharma by comparing valuation metrics of similar companies.Lyell Immunopharma is currently under evaluation in return on asset category among its peers.
Lyell Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | (125.21 M) | ||||
| Shares Outstanding | 279.22 M | ||||
| Shares Owned By Insiders | 14.06 % | ||||
| Shares Owned By Institutions | 61.64 % | ||||
| Number Of Shares Shorted | 9.6 M | ||||
| Price To Earning | 3.66 X | ||||
| Price To Book | 0.50 X | ||||
| Price To Sales | 4,189 X | ||||
| Revenue | 130 K | ||||
| Gross Profit | 84.68 M | ||||
| EBITDA | (226.76 M) | ||||
| Net Income | (234.63 M) | ||||
| Cash And Equivalents | 655.56 M | ||||
| Cash Per Share | 2.64 X | ||||
| Total Debt | 63.17 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 13.26 X | ||||
| Book Value Per Share | 2.07 X | ||||
| Cash Flow From Operations | (163.69 M) | ||||
| Short Ratio | 5.18 X | ||||
| Earnings Per Share | (0.79) X | ||||
| Price To Earnings To Growth | 0.68 X | ||||
| Target Price | 2.0 | ||||
| Number Of Employees | 224 | ||||
| Beta | -0.48 | ||||
| Market Capitalization | 263.89 M | ||||
| Total Asset | 750.03 M | ||||
| Retained Earnings | (1 B) | ||||
| Working Capital | 520.17 M | ||||
| Net Asset | 750.03 M |
About Lyell Immunopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lyell Immunopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lyell Immunopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lyell Immunopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 20.4 M | 12.7 M | |
| Total Revenue | 130 K | 123.5 K | |
| Cost Of Revenue | 20.2 M | 16.1 M | |
| Stock Based Compensation To Revenue | 362.18 | 380.29 | |
| Sales General And Administrative To Revenue | 515.25 | 541.02 | |
| Research And Ddevelopement To Revenue | 1.4 K | 1.5 K | |
| Capex To Revenue | 20.66 | 12.79 | |
| Ebit Per Revenue | -1.9 K | -1.8 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Lyell Immunopharma Piotroski F Score and Lyell Immunopharma Altman Z Score analysis. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.79) | Quarterly Revenue Growth 0.36 | Return On Assets (0.19) | Return On Equity (0.33) |
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.